top of page

Laxxon Medical
Mar 114 min read
Laxxon's Oral GLP-1 Agonist Treatment, LXM.2, Granted Funding by ESF Plus and the Free State of Thuringia
Laxxon has received a grant by Freistaat Thüringen and the ESF Plus (European Social Fund) for the further development of LXM.2.

Laxxon Medical
Feb 112 min read
Laxxon's New Generation Levodopa/Carbidopa Treatment, LXM.5, Granted Funding by ESF Plus and the Free State of Thuringia
Laxxon's New Generation Levodopa/Carbidopa for Parkinson's Disease project, LXM.5, has been awarded a grant.

Laxxon Medical
Jan 153 min read
Laxxon Medical Announces Positive Pilot PK Study Results (in Pigs) for Groundbreaking Oral GLP-1 Dosage Form
[New York, New York] – Laxxon Medical, a leading pharmaceutical technology company pioneering a new generation of advanced oral drug...
bottom of page